MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Triple Helix Framework
Industry
Architects: Small & Medium Size Business (SMBs), Product Development, De-Risking, Validation, Building Niche & Emerging Markets
Architects: Biotechnology_Proteomics
Neomorph
Organization & Developments: Neomorph
Parents
Neomorph
Children
*Strategies for protein degradation have been shown to solve critical problems in drug discovery by enabling researchers to target previously “undruggable” proteins that lack suitable binding pockets required for conventional drug activity.
*Targeted protein degradation offers opportunities to develop novel therapeutics across a broad range of disease areas, including oncology.
2024: Biogen buys in to molecular glues with Neomorph deal worth up to $1.45B
2025: Sticky, sticky, sticky: Neomorph tacks on another Big Pharma glue degrader deal with $1.6B AbbVie pact
Jumps
Finance & Acquisition: Neomorph
Key People: Neomorph